GenIbet Biopharmaceuticals
Providing tailored GMP solutions to turn ideas into tomorrow's medicines.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 20 % | - | 7 % | 46 % | 38 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 58 % | 56 % | 39 % | 47 % | 51 % | 46 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 47 % | 38 % | 24 % | 35 % | 40 % | 35 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
GenIbet is a cGMP biopharmaceutical Contract Manufacturing Organization (CMO) based in Portugal, 20 km west of Lisbon airport. The company operates a state-of-the-art facility spanning 1000 square meters, designed to meet the stringent demands of the biotechnology industry. GenIbet offers highly specialized services in microbial, cell culture, and viral processes, catering to the needs of gene therapies and vaccine production. The facility includes multiple production units such as a Bacterial Unit for BL2 fermentation, a Viral Unit for gene therapies and vaccines, an Animal Cell Culture Unit, and a Fill and Finish Unit for small-scale semi-automated processes.
GenIbet serves a diverse range of clients in the biopharmaceutical sector, including biotech companies, research institutions, and pharmaceutical firms. The company operates in the global biotechnology market, focusing on contract manufacturing services. GenIbet's business model revolves around providing specialized manufacturing capabilities to its partners, enabling them to bring innovative therapies and vaccines to market. Revenue is generated through long-term contracts and project-based engagements with its clients.
Keywords: cGMP, biopharmaceutical, CMO, microbial processes, cell culture, viral processes, gene therapies, vaccines, biotechnology, Portugal.